- Next-gen CAR-T therapy caused rapid, dramatic glioblastoma tumour shrinkage in trials
- Therapy targets multiple tumour markers and is infused directly into the brain
- Glioblastoma is aggressive, hard to treat, and often returns after standard therapies
A new experimental cancer treatment is offering fresh hope against one of the deadliest brain tumours. Research published in The New England Journal of Medicine, have reported that a next-generation CAR-T cell therapy led to rapid and dramatic shrinkage of glioblastoma tumours, even after just a single treatment. Glioblastoma is one of the most aggressive forms of brain cancer, with limited treatment options and a poor prognosis. Standard therapies such as surgery, radiation and chemotherapy often struggle to stop the disease from returning. Now, early clinical trial results suggest that reprogramming the body's own immune cells may provide a powerful new way to fight this cancer.
What the Study Found
The trial involved a small group of patients with recurrent glioblastoma who had already undergone standard treatments. After receiving the experimental CAR-T therapy, the results were striking:
- As observed in an MRI scan tumours began shrinking within 5 days of treatment
- Some patients experienced near-complete tumour regression
- In one case, tumour size dropped significantly within just two days and continued shrinking over time.
Researchers described the response as both "rapid and dramatic", highlighting how quickly the therapy appeared to take effect. However, the responses were not always permanent, and tumours eventually began to grow again in some patients.
Also read: Combined Drug Therapy Shows Promise Against Aggressive Childhood Brain Cancer: Study
What Makes This CAR-T Therapy Different?
CAR-T (chimeric antigen receptor T-cell) therapy works by taking a patient's immune cells, modifying them in a lab to better recognise cancer, and then infusing them back into the body. What sets this new approach apart is that it is a next-generation, dual-target therapy, designed to attack more than one marker on tumour cells at the same time. This is crucial because glioblastoma is highly complex and can evade treatments that target only a single pathway. By hitting multiple targets, the therapy aims to reduce the chances of the tumour escaping immune attack. Another key innovation is how the treatment is delivered. Instead of circulating through the bloodstream, the engineered cells are directly infused into the brain, allowing them to act more precisely on the tumour.
Why Glioblastoma Is So Hard to Treat
Glioblastoma has long been one of the most challenging cancers to manage.
- It grows rapidly and invades surrounding brain tissue
- It often resists conventional therapies
- It almost always returns after treatment
Even with the best available care, average survival is typically less than two years. Immunotherapy, which has transformed treatment for some blood cancers, has historically struggled to work against solid tumours like glioblastoma due to the tumour's complex environment and the brain's protective barriers.
A Step Forward With Limitations
While the results are encouraging, researchers stress that this is still early-stage research. The trial involved only a small number of patients, and although tumour shrinkage was dramatic, it was often temporary rather than long-lasting. This means more work is needed to:
- Extend the durability of the response
- Prevent tumour regrowth
- Ensure long-term safety
Scientists are already exploring ways to improve the therapy, including combining it with other treatments and refining how the engineered cells function in the body.
Why This Matters
Despite its limitations, the study represents a significant breakthrough. For decades, glioblastoma has remained one of the most stubborn cancers, with only modest improvements in survival. The fact that tumours can shrink so quickly with a single infusion suggests that CAR-T therapy may finally be making inroads into solid tumours. Experts say the findings could also have broader implications, potentially helping to advance immunotherapy for other hard-to-treat cancers. The new study shows that next-generation CAR-T therapy can trigger rapid and dramatic tumour shrinkage in glioblastoma, offering a glimmer of hope for a disease that has long resisted treatment. While the therapy is still in its early stages and not yet a cure, the findings mark an important step forward in cancer research. For patients and doctors alike, it signals something that has been rare in glioblastoma care: a genuinely promising new direction.
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information
